Annual Cash & Cash Equivalents
$126.59 M
+$96.84 M+325.46%
31 December 2023
Summary:
C4 Therapeutics annual cash & cash equivalents is currently $126.59 million, with the most recent change of +$96.84 million (+325.46%) on 31 December 2023. During the last 3 years, it has fallen by -$55.14 million (-30.34%). CCCC annual cash & cash equivalents is now -30.34% below its all-time high of $181.73 million, reached on 31 December 2020.CCCC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$59.65 M
-$13.46 M-18.42%
30 September 2024
Summary:
C4 Therapeutics quarterly cash and cash equivalents is currently $59.65 million, with the most recent change of -$13.46 million (-18.42%) on 30 September 2024. Over the past year, it has dropped by -$1.32 million (-2.17%). CCCC quarterly cash and cash equivalents is now -78.78% below its all-time high of $281.15 million, reached on 30 June 2021.CCCC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CCCC Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +325.5% | -2.2% |
| 3 y3 years | -30.3% | -63.4% |
| 5 y5 years | +248.6% | - |
CCCC Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -30.3% | +325.5% | -63.4% | +100.5% |
| 5 y | 5 years | -30.3% | +325.5% | -78.8% | +100.5% |
| alltime | all time | -30.3% | +325.5% | -78.8% | +100.5% |
C4 Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $59.65 M(-18.4%) |
| June 2024 | - | $73.11 M(-18.5%) |
| Mar 2024 | - | $89.66 M(-29.2%) |
| Dec 2023 | $126.59 M(+325.5%) | $126.59 M(+107.6%) |
| Sept 2023 | - | $60.97 M(+35.9%) |
| June 2023 | - | $44.88 M(-9.3%) |
| Mar 2023 | - | $49.48 M(+66.3%) |
| Dec 2022 | $29.75 M | $29.75 M(-40.0%) |
| Sept 2022 | - | $49.55 M(-13.5%) |
| June 2022 | - | $57.30 M(+24.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $46.00 M(-39.6%) |
| Dec 2021 | $76.12 M(-58.1%) | $76.12 M(-53.2%) |
| Sept 2021 | - | $162.75 M(-42.1%) |
| June 2021 | - | $281.15 M(+196.2%) |
| Mar 2021 | - | $94.91 M(-47.8%) |
| Dec 2020 | $181.73 M(+100.7%) | $181.73 M(+186.5%) |
| Sept 2020 | - | $63.43 M(-43.4%) |
| June 2020 | - | $112.15 M(+23.9%) |
| Dec 2019 | $90.55 M(+149.4%) | $90.55 M |
| Dec 2018 | $36.31 M | - |
FAQ
- What is C4 Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for C4 Therapeutics?
- What is C4 Therapeutics annual cash & cash equivalents year-on-year change?
- What is C4 Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for C4 Therapeutics?
- What is C4 Therapeutics quarterly cash and cash equivalents year-on-year change?
What is C4 Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CCCC is $126.59 M
What is the all time high annual cash & cash equivalents for C4 Therapeutics?
C4 Therapeutics all-time high annual cash & cash equivalents is $181.73 M
What is C4 Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CCCC annual cash & cash equivalents has changed by +$96.84 M (+325.46%)
What is C4 Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CCCC is $59.65 M
What is the all time high quarterly cash and cash equivalents for C4 Therapeutics?
C4 Therapeutics all-time high quarterly cash and cash equivalents is $281.15 M
What is C4 Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CCCC quarterly cash and cash equivalents has changed by -$1.32 M (-2.17%)